{"id":197652,"date":"2015-04-01T15:54:57","date_gmt":"2015-04-01T19:54:57","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/penn-medicine-researchers-smell-new-receptors-that-could-underlie-the-many-actions-of-the-anesthetic-drug-ketamine.php"},"modified":"2015-04-01T15:54:57","modified_gmt":"2015-04-01T19:54:57","slug":"penn-medicine-researchers-smell-new-receptors-that-could-underlie-the-many-actions-of-the-anesthetic-drug-ketamine","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nano-medicine\/penn-medicine-researchers-smell-new-receptors-that-could-underlie-the-many-actions-of-the-anesthetic-drug-ketamine.php","title":{"rendered":"Penn Medicine Researchers &quot;Smell&quot; New Receptors that Could Underlie the Many Actions of the Anesthetic Drug Ketamine"},"content":{"rendered":"<p><p>Contact Information         <\/p>\n<p>      Available for logged-in reporters only    <\/p>\n<p>    Newswise  PHILADELPHIA Penn Medicine researchers are continuing    their work in trying to understand the mechanisms through which    anesthetics work to elicit the response that puts millions of    Americans to sleep for surgeries each day. Their most recent    study looked at ketamine, an anesthetic discovered in the 1960s    and more recently prescribed as an anti-depressant at low    doses. Through collaboration with the University of    Pennsylvanias department of Chemistry and scientists at the    Duke University Medical Center, researchers at Penns Perelman    School of Medicine have identified an entirely new class of    receptors that ketamine binds in the body, which may underlie    its diverse actions. The work is published in this weeks issue    of Science Signaling.  <\/p>\n<p>    Ketamine is believed to act through glutamate receptors to    produce anesthesia, but this is unlikely to explain the    anti-depressant effect; most antidepressants target G-protein    coupled receptors (GCPRs), the largest class of druggable    receptors, located in the bodys central nervous system (CNS).    To explore the GCPR class of receptors, the investigators    screened proteins present in the mouse nasal epithelium,    olfactory receptors (ORs), which typically respond very    selectively to compounds in the air, giving rise to smell. It    turns out that these ORs are also present throughout the    nervous system. ORs make up the largest group of GCPRs, yet    they are unexplored as transducing components of general    anesthesia or of antidepressants.  <\/p>\n<p>    Our hope is that we can visualize the precise molecular    interactions between ketamine and ORs, and in turn, learn how    this old drug interacts with these and other GCPRs throughout    the central nervous system, says the studys senior author,    Roderic Eckenhoff, MD, the Austin Lamont    Professor of Anesthesiology and Critical Care at Penn.  <\/p>\n<p>    Eckenhoff and a team at Duke University began their study by    screening ORs of mice and found that ketamine activated only    two types out of more than several hundred, known as MOR136 and    MOR139. They then used computational modeling and simulation    approaches with Jeffery Saven, PhD, professor of Chemistry at Penn    to generate structural models of these ORs and to understand    exactly how they recognize ketamine. Several amino acid    residues were identified as critical determinants. The team    found that by mutating these amino acids, they could turn    ketamine responsiveness both on and off.  <\/p>\n<p>    They also tested these conclusions in mice by stimulating the    olfactory epithelium via intranasal application of ketamine and    showed that olfactory sensory neurons that expressed these    unique ORs responded to ketamine, suggesting that ORs may truly    serve as functional targets for ketamine.  <\/p>\n<p>    Here we provide evidence that ketamine has a highly specific    interaction with the ORs, indicating that at least some of    ketamines actions may result from these or other GCPRs in the    central nervous system, says Eckenhoff, noting that our    rigorous combination of simulation and experiment indicates    that we can design receptors to respond specifically to certain    drugs, which gets us one step closer to doing the opposite and    designing drugs to interact specifically with certain    receptors.  <\/p>\n<p>    Additional Penn authors include Jose Manuel Perez-Aguilar and    Lu Gao, department of Chemistry.  <\/p>\n<p>    This work was funded by NIH grants (DC010857, DC012095, and    GM55876), the National Science Foundation through the Penn    Nano\/Bio Interface Center (NSEC DMR08-3202).    # # #    Penn Medicine is one of the world's leading academic medical    centers, dedicated to the related missions of medical    education, biomedical research, and excellence in patient care.    Penn Medicine consists of the Raymond and Ruth Perelman School    of Medicine at the University of Pennsylvania (founded in 1765    as the nation's first medical school) and the University of    Pennsylvania Health System, which together form a $4.9 billion    enterprise.    The Perelman School of Medicine has been ranked among the top    five medical schools in the United States for the past 17    years, according to U.S. News & World Report's survey of    research-oriented medical schools. The School is consistently    among the nation's top recipients of funding from the National    Institutes of Health, with $409 million awarded in the 2014    fiscal year.    The University of Pennsylvania Health System's patient care    facilities include: The Hospital of the University of    Pennsylvania -- recognized as one of the nation's top \"Honor    Roll\" hospitals by U.S. News & World Report; Penn    Presbyterian Medical Center; Chester County Hospital; Penn    Wissahickon Hospice; and Pennsylvania Hospital -- the nation's    first hospital, founded in 1751. Additional affiliated    inpatient care facilities and services throughout the    Philadelphia region include Chestnut Hill Hospital and Good    Shepherd Penn Partners, a partnership between Good Shepherd    Rehabilitation Network and Penn Medicine.    Penn Medicine is committed to improving lives and health    through a variety of community-based programs and activities.    In fiscal year 2014, Penn Medicine provided $771 million to    benefit our community.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>More: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.newswise.com\/articles\/view\/632093\/?sc=rsmn\/RK=0\/RS=_P5jvHEk7Hw8lK5MKXZxi_u3yyg-\" title=\"Penn Medicine Researchers &quot;Smell&quot; New Receptors that Could Underlie the Many Actions of the Anesthetic Drug Ketamine\">Penn Medicine Researchers &quot;Smell&quot; New Receptors that Could Underlie the Many Actions of the Anesthetic Drug Ketamine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Contact Information Available for logged-in reporters only Newswise PHILADELPHIA Penn Medicine researchers are continuing their work in trying to understand the mechanisms through which anesthetics work to elicit the response that puts millions of Americans to sleep for surgeries each day. Their most recent study looked at ketamine, an anesthetic discovered in the 1960s and more recently prescribed as an anti-depressant at low doses. Through collaboration with the University of Pennsylvanias department of Chemistry and scientists at the Duke University Medical Center, researchers at Penns Perelman School of Medicine have identified an entirely new class of receptors that ketamine binds in the body, which may underlie its diverse actions <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nano-medicine\/penn-medicine-researchers-smell-new-receptors-that-could-underlie-the-many-actions-of-the-anesthetic-drug-ketamine.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-197652","post","type-post","status-publish","format-standard","hentry","category-nano-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/197652"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=197652"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/197652\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=197652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=197652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=197652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}